179 related articles for article (PubMed ID: 7585041)
41. Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram.
Pettipher ER; Labasi JM; Salter ED; Stam EJ; Cheng JB; Griffiths RJ
Br J Pharmacol; 1996 Apr; 117(7):1530-4. PubMed ID: 8730750
[TBL] [Abstract][Full Text] [Related]
42. The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide.
Greten TF; Eigler A; Sinha B; Moeller J; Endres S
Int J Immunopharmacol; 1995 Jul; 17(7):605-10. PubMed ID: 8586489
[TBL] [Abstract][Full Text] [Related]
43. DAB389IL-2 suppresses autoimmune inflammation in the CNS and inhibits T cell-mediated lysis of glial target cells.
Bhopale MK; Hilliard B; Constantinescu CS; Fujioka T; Ventura E; Phillips SM; Rostami A
Exp Mol Pathol; 2014 Feb; 96(1):108-17. PubMed ID: 23872438
[TBL] [Abstract][Full Text] [Related]
44. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
45. The inhibitory effect of rolipram on TNF-alpha production in mouse blood ex vivo is dependent upon the release of corticosterone and adrenaline.
Pettipher ER; Eskra JD; Labasi JM
Cytokine; 1997 Aug; 9(8):582-6. PubMed ID: 9245486
[TBL] [Abstract][Full Text] [Related]
46. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
47. Effects of phosphodiesterase inhibitors on cytokine production by microglia.
Yoshikawa M; Suzumura A; Tamaru T; Takayanagi T; Sawada M
Mult Scler; 1999 Apr; 5(2):126-33. PubMed ID: 10335522
[TBL] [Abstract][Full Text] [Related]
48. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors.
Wachtel H; Schneider HH
Neuropharmacology; 1986 Oct; 25(10):1119-26. PubMed ID: 2946976
[TBL] [Abstract][Full Text] [Related]
49. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
[TBL] [Abstract][Full Text] [Related]
50. Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system.
Körner H; Lemckert FA; Chaudhri G; Etteldorf S; Sedgwick JD
Eur J Immunol; 1997 Aug; 27(8):1973-81. PubMed ID: 9295034
[TBL] [Abstract][Full Text] [Related]
51. Chronological changes of CD4(+) and CD8(+) T cell subsets in the experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis.
Sonobe Y; Jin S; Wang J; Kawanokuchi J; Takeuchi H; Mizuno T; Suzumura A
Tohoku J Exp Med; 2007 Dec; 213(4):329-39. PubMed ID: 18075237
[TBL] [Abstract][Full Text] [Related]
52. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
[TBL] [Abstract][Full Text] [Related]
53. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta.
Issazadeh S; Ljungdahl A; Höjeberg B; Mustafa M; Olsson T
J Neuroimmunol; 1995 Sep; 61(2):205-12. PubMed ID: 7593556
[TBL] [Abstract][Full Text] [Related]
54. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis.
Paintlia AS; Paintlia MK; Singh I; Skoff RB; Singh AK
Glia; 2009 Jan; 57(2):182-93. PubMed ID: 18720408
[TBL] [Abstract][Full Text] [Related]
55. Antidepressant properties of some phosphodiesterase inhibitors.
Przegaliński E; Bigajska K
Pol J Pharmacol Pharm; 1983; 35(3):233-40. PubMed ID: 6194518
[TBL] [Abstract][Full Text] [Related]
56. Mechanisms of recovery from experimental allergic encephalomyelitis induced with myelin basic protein peptide 68-86 in Lewis rats: a role for dendritic cells in inducing apoptosis of CD4+ T cells.
Xiao BG; Huang YM; Xu LY; Ishikawa M; Link H
J Neuroimmunol; 1999 Jun; 97(1-2):25-36. PubMed ID: 10408975
[TBL] [Abstract][Full Text] [Related]
57. Regulation of IL-15-stimulated TNF-alpha production by rolipram.
Kasyapa CS; Stentz CL; Davey MP; Carr DW
J Immunol; 1999 Sep; 163(5):2836-43. PubMed ID: 10453029
[TBL] [Abstract][Full Text] [Related]
58. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages.
Schade FU; Schudt C
Eur J Pharmacol; 1993 Jan; 230(1):9-14. PubMed ID: 8381357
[TBL] [Abstract][Full Text] [Related]
59. Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis.
Sánchez AJ; Puerta C; Ballester S; González P; Arriaga A; García-Merino A
J Neuroimmunol; 2005 Nov; 168(1-2):13-20. PubMed ID: 16182379
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of human cytokine production and effects of pharmacological agents in a heterologous system in vivo.
Griswold DE; Hillegass LM; O'Leary-Bartus J; Lee JC; Laydon JT; Torphy TJ
J Immunol Methods; 1996 Sep; 195(1-2):1-5. PubMed ID: 8814313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
